[Spectacillin-a new-developed multi-effective penicillin in treating chronic bronchoulmonary diseases author's transl].
50 patients with a chronic disease of the bronchopulmonary system, within the therapy of an acute exacerbation received in addition to bronchosecretolytics, spasmolytic substances, and corticosterones the substance 'Spectacillin' in a dosage ranging from 2 to 6 grams per day during the period of 2 weeks. The acute exacerbation has been stopped in 34 patients and there-by the recurrence could be prevented. Although in 9 patients a clinical improvement has been obtained, no germ elimination could be ascertained; 7 cases of disease remained uninfluenced. The evalution is documentated by the clinical and laboratory findings, the germ analysis and the test of pulmonary functions. The compatibality can be evaluated as well-effective; especially the low rate of exanthema (2 patients) is to be emphasized.
D001314:Auscultation; D001987:Bronchiectasis / Q000150:complications; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D001996:Bronchopneumonia / Q000150:complications; D002908:Chronic Disease; D003371:Cough; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012008:Recurrence; D013183:Sputum; D013997:Time Factors
D010397:Penicillanic Acid
Spectacillin-ien neues Breitbandpenicillin in der Behandlung chronischer bronchopulmonaler Erkrankungen